The federal government regulates prices of patented pharmaceutical products
with the objective of protecting consumers against excessive prices. Regulation has very likely been
responsible for bringing Canadas prices for patented medicines roughly in line with European
comparators. Prices of generic products, which are not regulated, are relatively high although high
penetration of the Canadian market has been achieved. All Canadians have coverage for drugs provided in
hospitals through a publicly financed scheme that furnishes hospital and physician services free of charge
to patients. Drugs dispensed outside the hospital setting are not included among the insured benefits
guaranteed by the Canadian Health Act. Consequently, two-thirds of the Canadian population, including
most employees and their families, obtains such coverage through private health insurance, while most
senior citizens, together with designated groups of vulnerable populations, are covered by provincial,
territorial or federal plans. In most cases, patients share in the costs of reimbursed medicines through copayments
or co-insurance, sometimes after meeting a deductible. The lack of protection against the risk of
catastrophic out-of-pocket spending for drugs remains an issue for a small part of the Canadian population,
concentrated in the Atlantic Provinces. Reflecting these coverage and reimbursement arrangements, 54%
of drug expenditures are financed by private insurances and households. Drug expenditures have been
increasing very rapidly in recent years. Formulary management, now facilitated by a government initiative
to undertake common drug reviews, and the promotion of generic substitution have been the main levers
used by public plans to improve the efficiency of drug expenditures. Private plans have historically
covered all medicines authorised for sale in Canada, although this is changing in light of cost pressure.
Overall, new drugs are available in the Canadian market on a timely basis, but maintaining comprehensive
availability and accessibility may be an emerging challenge.
http://www.oecd.org/dataoecd/21/40/37868186.pdfOkay, regulated. But then again it hasn't meant that pharma has left the country, or Europe,, in the lurch. And pharma had their patent periods lenghtened to protect from generic compeitors....
The point is that the prices are contained, drugs continue to be manufacture, and developed.
Its a reason that costs are held in check versus the runaway inflation in the US.
Is that runaway inflation due to efficient market competition?